Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.

[1]  T. Erkinjuntti,et al.  CSF in Alzheimer's disease: Studies on blood-brain barrier function and intrathecal protein synthesis , 1985, Journal of the Neurological Sciences.

[2]  D. Selkoe,et al.  Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[4]  J. O'dell,et al.  Unexpected presence of polyreactive catalytic antibodies in IgG from unimmunized donors and decreased levels in rheumatoid arthritis. , 1995, Journal of immunology.

[5]  S. Paul,et al.  Site-directed mutagenesis of proteolytic antibody light chain. , 1995, Journal of molecular biology.

[6]  Hans Förstl,et al.  Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay* , 1996, The Journal of Biological Chemistry.

[7]  B. Solomon,et al.  Disaggregation of Alzheimer beta-amyloid by site-directed mAb. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  B. Solomon,et al.  Disaggregation of Alzheimer β-amyloid by site-directed mAb , 1997 .

[9]  J. Hardy,et al.  A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. , 2000, Nature.

[10]  H. Nakauchi,et al.  Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes. , 2000, Nature immunology.

[11]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[12]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[13]  Y. X. Zhou,et al.  Phosphonate Ester Probes for Proteolytic Antibodies* , 2001, The Journal of Biological Chemistry.

[14]  D. Holtzman,et al.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A mechanism-based probe for gp120-Hydrolyzing antibodies. , 2002, Bioorganic & medicinal chemistry letters.

[17]  L. Lue,et al.  Modeling Alzheimer's disease immune therapy mechanisms: Interactions of human postmortem microglia with antibody‐opsonized amyloid beta peptide , 2002, Journal of neuroscience research.

[18]  M. Wolfe.  Secretase as a target for Alzheimer's disease. , 2002, Current topics in medicinal chemistry.

[19]  N. Relkin,et al.  Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals , 2002, Experimental Gerontology.

[20]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[21]  M. Sierks,et al.  Degradation of β-Amyloid by Proteolytic Antibody Light Chains† , 2003 .

[22]  M. Sierks,et al.  Degradation of beta-amyloid by proteolytic antibody light chains. , 2003, Biochemistry.

[23]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[24]  Y. Lyubchenko,et al.  Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. , 2004, Biochemistry.

[25]  D. Wilcock,et al.  Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage , 2004, Journal of Neuroinflammation.

[26]  H. Möller,et al.  Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[27]  A. Edmundson,et al.  Ontogeny of Proteolytic Immunity , 2004, Journal of Biological Chemistry.

[28]  P. Seubert,et al.  Current progress in beta-amyloid immunotherapy. , 2004, Current opinion in immunology.

[29]  Y. Nishiyama,et al.  Antibodies as defensive enzymes , 2005, Springer Seminars in Immunopathology.

[30]  E. Zamrini,et al.  Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Aβ and RAGE peptides , 2004, Neurobiology of Aging.

[31]  D. Morgan.  Mechanisms of A beta plaque clearance following passive A beta immunization. , 2005, Neuro-degenerative diseases.

[32]  D. Holtzman,et al.  IgG-Assisted Age-Dependent Clearance of Alzheimer's Amyloid β Peptide by the Blood–Brain Barrier Neonatal Fc Receptor , 2005, The Journal of Neuroscience.

[33]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[34]  C. Slaughter,et al.  Crystal structure of a glycosylated Fab from an IgM cryoglobulin with properties of a natural proteolytic antibody. , 2006, The Biochemical journal.

[35]  S. Honda,et al.  Molecular and functional characteristics of the Fcα/μR, a novel Fc receptor for IgM and IgA , 2006, Springer Seminars in Immunopathology.

[36]  S. Honda,et al.  Molecular and functional characteristics of the Fcalpha/muR, a novel Fc receptor for IgM and IgA. , 2006, Springer seminars in immunopathology.

[37]  L. Mucke,et al.  A network dysfunction perspective on neurodegenerative diseases , 2006, Nature.

[38]  W. Banks,et al.  Anti-amyloid beta protein antibody passage across the blood–brain barrier in the SAMP8 mouse model of Alzheimer's disease: An age-related selective uptake with reversal of learning impairment , 2007, Experimental Neurology.

[39]  M. Staufenbiel,et al.  Vessel ultrastructure in APP23 transgenic mice after passive anti-Aβ immunotherapy and subsequent intracerebral hemorrhage , 2007, Neurobiology of Aging.

[40]  D. Selkoe,et al.  Aβ Oligomers – a decade of discovery , 2007, Journal of neurochemistry.

[41]  R. Nitsch,et al.  Aβ Oligomer-Mediated Long-Term Potentiation Impairment Involves Protein Phosphatase 1-Dependent Mechanisms , 2007, The Journal of Neuroscience.

[42]  J. Symerský,et al.  Autoantibody-catalyzed Hydrolysis of Amyloid β Peptide* , 2008, Journal of Biological Chemistry.